To the Editor: Mycobacterium ulcerans disease (Buruli ulcer) is a neglected and emerging tropical dis-ease (1). It often leads to extensive destruction of skin and soft tissue with the formation of large ulcers (2). In 2004, the World Health Organization (WHO) recommended the combina-tion treatment of rifampin/streptomy-cin for patients with this disease (3). According to WHO, development of new antimicrobial drug treatment is one of the major advances since the establishment of the Global Buruli Ulcer Initiative (1). Treatment with rifampin/streptomycin for >4 weeks can inhibit the growth of M. ulcerans in preulcerative lesions (4). In other patients, despite 4 weeks of treatment, lesions may deteriorate. Whether this treatment is less effi cacious in persons with HIV infection is unknown
展开▼
